Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 93

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 93
---
 pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.

Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the Depositary Shares for the applicable restricted period, as defined in Regulation M, prior to the
commencement of the distribution. In addition, the selling shareholders will be subject to applicable provisions of the Exchange Act and
the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Depositary Shares
by the selling shareholders or any other person. We will make copies of this prospectus available to the selling shareholders and have
informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act).

| 48 |

<div align='center'>LEGAL MATTERS</div>

Brown Rudnick LLP, London,
United Kingdom has passed upon certain legal matters regarding the securities offered hereby.

<div align='center'>EXPERTS</div>

The financial statements
as of December 31, 2024, and for the year then ended, incorporated by reference into this prospectus and in the registration statement
have been so incorporated in reliance on a report PKF Littlejohn LLP, an independent registered accounting firm, given on authority of
said firm as experts in auditing and accounting. The report on the financial statements for the year ended December 31, 2024 contains
an explanatory paragraph regarding our ability to continue as a going concern.

PKF Littlejohn LLP, London,
United Kingdom, is a member of the Institute of Chartered Accountants in England and Wales.

The
financial statements of Biodexa Pharmaceuticals PLC as of December 31, 2023, and for each of the three years in the period then ended,
incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on a report of Forvis
Mazars LLP (then-named Mazars LLP), an independent